Project List
List projects.
Fields
id (integer)
Primary key.
Expansions
To activate relation expansion add the desired fields as a comma separated
list to the expand query parameter like this:
?expand=<field>,<field>,<field>,...
The following relational fields can be expanded:
organizationcategorytypepartner_functionmanagercontactstatusgrantresearcheventstudylanguageprogramfunders
Filters
To filter for exact value matches:
?<fieldname>=<value>
Possible exact filters:
organizationcategorymanagercontactstatusgrantresearchstudylanguagefundersprogram
For advanced filtering use lookups:
?<fieldname>__<lookup>=<value>
All fields with advanced lookups can also be used for exact value matches as described above.
Possible advanced lookups:
begin_planned:gt,gte,lt,ltebegin_effective:gt,gte,lt,lteend_planned:gt,gte,lt,lteend_effective:gt,gte,lt,lte
GET /v1/research/project/?format=api&offset=180&ordering=begin_planned
{ "count": 2265, "next": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=200&ordering=begin_planned", "previous": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=160&ordering=begin_planned", "results": [ { "id": 2663, "title": { "de": "Doktoratskolleg \"Metabolische und Kardiovaskuläre Erkrankungen\"", "en": "Doktoratskolleg: \"Metabolic and cardiovascular disease\"" }, "short": "DK_METABOL_DISORDERS", "url": null, "abstract": { "de": "Projekt 1 erarbeit die subuellulären Mechanismen getriggerter Arrhythmien unter besonderer Berücksichtigung eines gestörten Funktion des Ryanodin-Rezeptors des sarkoplasmatischen Retikulums.\r\n\r\nProjekt 2 untersucht den Einfluss von milder Hypothermie auf Hämodynamik, zelluläre und subzelluläre Funktion im Schockmodell und Sepsismodell.", "en": null }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2010-07-01T02:00:00+02:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2014-06-30T02:00:00+02:00", "assignment": "2009-12-18T01:00:00+01:00", "program": 66, "subprogram": null, "organization": 14083, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "W1226", "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 1819, "title": { "de": "Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo", "en": "Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo" }, "short": "Nano-Health: 4D Imaging of Stem Cells", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-05-18T11:50:29+02:00", "program": null, "subprogram": "Nano-Health", "organization": 14082, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 3, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1819-50747-12" ] }, { "id": 2654, "title": { "de": "Doktoratskolleg \"Metabolische und kardiovaskuläre Erkrankungen\" ", "en": "Doktoratskolleg \"Metabolic disorders and cellular dysfunction\" " }, "short": "DK_METABOL_DISORDERS", "url": null, "abstract": { "de": "Proteomic investigation of lipotoxicity in tumor-associated cachexia\r\nObjective: To elucidate possible causes and effects of tumor-induced lipotoxicity on the proteome level.\r\nCachexia is commonly recognized as progressive weight loss with depletion of host reserves of adipose tissue and skeletal muscle and associated with cancers of gastrointestinal tract and lung. Survival of cancer patients is directly related to weight loss. The reduction of food intake alone is unable to explain the metabolic changes seen in cachexia. Moreover, loss of muscle and adipose tissue precedes the fall in food intake. The causes and mechanisms responsible for tumor-associated cachexia remain to be unravelled. Preliminary data generated in Gerald Hoefler´s laboratory demonstrate an involvement of adipose triglyceride lipase (ATGL) in the development of cachexia. While implantation of Lewis lung carcinoma cells into wild-type mice resulted in a vast reduction of gastrognemious muscle and white adipose tissue and a minor reduction in heart weight, none of these effects were seen in ATGL-ko mice.\r\nTissues from cachexia mouse models will be obtained from G. Hoefler. Proteomes from gastrognemious muscle, adipose tissues, liver, heart and spleen of wild-type and ATGL-ko mice with and without transplanted tumor will be profiled with respect to protein abundance by differential gelelectrophoresis (DIGE) and/or isotope labeling, liquid chromatography and mass spectrometry (LC-MS). Phosphoproteomics of selected cellular fractions will be performed using immobilized metal affinity chromatography (IMAC, TiO2) for phosphopeptide enrichment, isotopic labeling for quantification, LC-MS with phospho-group neutral loss scanning and database search for phospho-group modifications. Differences in lipase and esterase activities will be assessed by activity-based proteomics employing suitable probes (developed by the applicant) and by standard proteomic techniques.\r\n\r\nRegulatory and compensatory mechanisms of lipolytic pathways\r\nBackground: While the lipolytic proteome of mouse adipose tissue has been identified (3), many of the underlying regulatory processes remain unknown. Therefore, regulatory and compensatory mechanisms of lipolytic pathways as well as changes in the overall proteome will be determined upon shut down of individual pathways (e.g. in hormone sensitive lipase (HSL)- and ATGL-deficient mice). The phenotypes of the respective mouse models differ greatly with regard to body weight, lipid accumulation, fertility and organ specific defects. Thus, large effects are expected to be observed on the protein level in adipose and other tissues as well as in macrophages and foam cells.\r\nObjective: To elucidate the underlying regulatory, compensatory and pathogenic mechanisms of lipid accumulation on the proteome level.\r\nProteins interacting with recently identified lipases, as well as lipid droplet-associated proteins, which might regulate substrate accessibility, will be isolated from tissue fractions or cell lines, identified by LC-MS and analyzed for the presence of isomers and post-translational modifications, especially phosphorylation. Related tissue/cell fractions or immunoprecipitations will be profiled with respect to protein abundance by DIGE and/or isotopic labelling and LC-MS. Selected proteins will be confirmed by Western blotting. Phosphoproteomics and activity-based proteomics will be applied as described in Project 1.\r\n", "en": null }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2010-07-01T02:00:00+02:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2014-06-30T02:00:00+02:00", "assignment": "2010-10-20T13:09:58+02:00", "program": 66, "subprogram": null, "organization": 28394, "category": 10, "type": 10, "partner_function": 2, "manager": 58794, "contact": 58794, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "W1226", "ethics_committee": null, "edudract_number": null, "persons": [ "2654-58794-10" ] }, { "id": 2659, "title": { "de": "Doktoratskolleg \"Metabolische und kardiovaskuläre Erkrankungen\" ", "en": "Doktoratskolleg: \"Metabolic and cardiovascular disease\"" }, "short": "DK_METABOL_DISORDERS", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2010-07-01T02:00:00+02:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2014-06-30T02:00:00+02:00", "assignment": "2010-10-20T13:09:58+02:00", "program": 66, "subprogram": null, "organization": 14021, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "W1226", "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 1821, "title": { "de": "Nano-Health: Nano-Plaque-Extension", "en": "Nano-Health: Nano-Plaque-Extension" }, "short": "Nano-Plaque-Extension", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2012-01-28T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-05-18T13:05:25+02:00", "program": null, "subprogram": "Nano-Health Verlängerung", "organization": 14028, "category": 10, "type": 10, "partner_function": 2, "manager": 52854, "contact": 52854, "status": 2, "research": 3, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1821-52854-10" ] }, { "id": 1820, "title": { "de": "NANO-AS: Nano-Tox-Verlängerung", "en": "NANO-AS: Nano-Tox-Verlängerung" }, "short": "NANO-AS", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-05-18T12:36:34+02:00", "program": null, "subprogram": "Nano-Health", "organization": 28394, "category": 10, "type": 10, "partner_function": 2, "manager": 53900, "contact": 53900, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1820-53900-10" ] }, { "id": 2658, "title": { "de": "Doktoratskolleg \"Metabolische und kardiovaskuläre Erkrankungen\" ", "en": "Doktoratskolleg: \"Metabolic and cardiovascular disease\"" }, "short": "DK_METABOL_DISORDERS", "url": null, "abstract": { "de": null, "en": "Identifying the molecular and regulatory mechanisms of HDL metabolism at the BBB will help to uncover the protective role of HDL against lipid-related neurodegenerative diseases such as Alzheimers disease.\r\nDuring the first funding period of the DK-Plus, students in U. Panzenboecks group will characterize phospholipid transfer protein function at the BBB to test the hypothesis if PLTP expression in cerebrovascular endothelial cells (EC) can be modulated and is involved in HDL remodelling and in lipid transport between the brain and the circulation. In a second show case the student will investigate the capacity of HDL particles to mediate/facilitate bidirectional oxysterol transport across the BBB and will aim to identify oxysterol transporting proteins in brain capillary EC. \r\n" }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2010-07-01T02:00:00+02:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2014-06-30T02:00:00+02:00", "assignment": "2010-10-20T13:09:58+02:00", "program": 66, "subprogram": null, "organization": 14014, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "W1226", "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2660, "title": { "de": "Doktoratskolleg \"Metabolische und kardiovaskuläre Erkrankungen\" ", "en": "Doktoratskolleg: \"Metabolic and cardiovascular disease\"" }, "short": "DK_METABOL_DISORDERS", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2010-07-01T02:00:00+02:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2014-06-30T02:00:00+02:00", "assignment": "2010-10-20T13:09:58+02:00", "program": 66, "subprogram": null, "organization": 14081, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "W1226", "ethics_committee": null, "edudract_number": null, "persons": [ "2660-66436-12" ] }, { "id": 1732, "title": { "de": "Zerebrale und peripher-muskuläre Gewebssättigung unmittelbar nach der Geburt [Postpartale zerebrale und periphere Oxygenierung bei reifen Neugeborenen und Frühgeborenen]", "en": "Transition after birth: cerebral and peripheral muscle oxygenation in term and preterm neonates" }, "short": "Oxygenierung", "url": null, "abstract": { "de": "Mit Nah-Infrarot Spektroskopie (NIRS) kann die Oxygenierung in verschiedenen Gewebsregionen gemessen werden. Zahlreiche Studien bei reifen Neugeborenen und Frühgeborenen wurden bereits durchgeführt, wobei es jedoch noch keine Daten der zerebralen und peripher-muskulären Oxygenierung unmittelbar nach der Geburt gibt. \r\nZiel der vorliegenden Studie ist es daher, die zerebrale und peripher-muskuläre Oxygenierung unmittelbar nach der Geburt mit NIRS zu messen und zu analysieren. Sollte eine Atemunterstützung mit Maske notwendig sein, wird der Einfluss von \"continuous positive airway pressure\" (CPAP) oder \"positive pressure ventilation\" (PPV) analysiert. Das Studiendesign ist prospektiv beobachtend.\r\nNIRS wird kombiniert mit nicht-invasivem Monitoring der arteriellen Sauerstoffsättigung, der Herzfrequenz, der Hämoglobinkonzentration, des Blutdrucks, mit einer Videodokumentation und -bei Atemunterstützung mit CPAP oder PPV- mit einem Atemfunktionsmonitoring.", "en": "Mit Nah-Infrarot Spektroskopie (NIRS) kann die Oxygenierung in verschiedenen Gewebsregionen gemessen werden. Zahlreiche Studien bei reifen Neugeborenen und Frühgeborenen wurden bereits durchgeführt, wobei es jedoch noch keine Daten der zerebralen und peripher-muskulären Oxygenierung unmittelbar nach der Geburt gibt. \r\nZiel der vorliegenden Studie ist es daher, die zerebrale und peripher-muskuläre Oxygenierung unmittelbar nach der Geburt mit NIRS zu messen und zu analysieren. Sollte eine Atemunterstützung mit Maske notwendig sein, wird der Einfluss von \"continuous positive airway pressure\" (CPAP) oder \"positive pressure ventilation\" (PPV) analysiert. Das Studiendesign ist prospektiv beobachtend.\r\nNIRS wird kombiniert mit nicht-invasivem Monitoring der arteriellen Sauerstoffsättigung, der Herzfrequenz, der Hämoglobinkonzentration, des Blutdrucks, mit einer Videodokumentation und -bei Atemunterstützung mit CPAP oder PPV- mit einem Atemfunktionsmonitoring." }, "begin_planned": "2009-04-01T02:00:00+02:00", "begin_effective": "2009-04-01T02:00:00+02:00", "end_planned": "2011-03-31T02:00:00+02:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-01-19T12:54:11+01:00", "program": 79, "subprogram": null, "organization": 14094, "category": 10, "type": 10, "partner_function": 4, "manager": 50907, "contact": 50907, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1732-50907-10" ] }, { "id": 2391, "title": { "de": "Einfluss der Knochenentnahmetechnik auf die Osteoblastenaktivität", "en": "Effect of Bone Harvesting Methods to the Osteoblast activity" }, "short": "KNOCHENENTNAHME_OSTEOBLAST", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-04-01T02:00:00+02:00", "begin_effective": "2011-01-26T01:00:00+01:00", "end_planned": "2010-10-01T02:00:00+02:00", "end_effective": "2017-12-31T01:00:00+01:00", "assignment": "2011-02-04T09:47:14+01:00", "program": null, "subprogram": null, "organization": 14057, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 4, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 1940, "title": { "de": "Altered prostaglandin receptor function in patients with aspirin intolerance", "en": "Altered prostaglandin receptor function in patients with aspirin intolerance" }, "short": "Prostaglandin receptor function", "url": null, "abstract": { "de": "Prostaglandin E2 (PGE2) limitiert in der Lunge immunologische und entzündliche Prozesse. Eosinophile Granulozyten spielen eine entscheidende Rolle bei der Pathogenese von Asthma bronchiale. Etwa 10% der Asthmapatienten vertragen keine Analgetika vom Typ der nichtsteroidalen Antirheumatika (z.B. Aspirin). Daher ist eine effektive Schmerz- und Entzündungstherapie bei diesen Patienten schwierig. Wir konnten zeigen, dass PGE2 hemmende Effekte an eosinophilen Granulozyten hat. Die Effekte von PGE2 werden durch vier Rezeptoren vermittelt. Wir untersuchen, inwieweit die Wirkungen von PGE2 auf Eosinophile von Patienten mit Aspirin-Unverträglichkeit verändert sind und welche Rolle die PGE2 Rezeptoren spielen. Als Vergleich dienen gesunde Probanden, allergische Patienten ohne Asthma und Asthmatiker ohne Aspirin-Unverträglichkeit. Diese Studie soll das Verständnis der Rolle von PGE2 bei Asthma und Aspirin-Unverträglichkeit erweitern, und möglicherweise neue therapeutische Optionen eröffen.", "en": "Prostaglandin E2 (PGE2) limitiert in der Lunge immunologische und entzündliche Prozesse. Eosinophile Granulozyten spielen eine entscheidende Rolle bei der Pathogenese von Asthma bronchiale. Etwa 10% der Asthmapatienten vertragen keine Analgetika vom Typ der nichtsteroidalen Antirheumatika (z.B. Aspirin). Daher ist eine effektive Schmerz- und Entzündungstherapie bei diesen Patienten schwierig. Wir konnten zeigen, dass PGE2 hemmende Effekte an eosinophilen Granulozyten hat. Die Effekte von PGE2 werden durch vier Rezeptoren vermittelt. Wir untersuchen, inwieweit die Wirkungen von PGE2 auf Eosinophile von Patienten mit Aspirin-Unverträglichkeit verändert sind und welche Rolle die PGE2 Rezeptoren spielen. Als Vergleich dienen gesunde Probanden, allergische Patienten ohne Asthma und Asthmatiker ohne Aspirin-Unverträglichkeit. Diese Studie soll das Verständnis der Rolle von PGE2 bei Asthma und Aspirin-Unverträglichkeit erweitern, und möglicherweise neue therapeutische Optionen eröffen." }, "begin_planned": "2009-04-01T02:00:00+02:00", "begin_effective": "2010-01-01T01:00:00+01:00", "end_planned": "2011-03-31T02:00:00+02:00", "end_effective": "2013-09-30T02:00:00+02:00", "assignment": "2009-10-01T18:22:11+02:00", "program": 79, "subprogram": null, "organization": 14022, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2008, "title": { "de": "Ganganalysen bei Kindern mit Morbus Perthes", "en": "Ganganalysen bei Kindern mit Morbus Perthes" }, "short": "Morbus Perthes", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-04-01T02:00:00+02:00", "begin_effective": "2009-04-01T02:00:00+02:00", "end_planned": "2009-08-31T02:00:00+02:00", "end_effective": "2012-07-31T02:00:00+02:00", "assignment": "2009-12-04T11:57:57+01:00", "program": null, "subprogram": "Land Steiermark Abteilung 3", "organization": 14049, "category": 10, "type": 10, "partner_function": 4, "manager": 65038, "contact": 65038, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2008-65038-10" ] }, { "id": 1931, "title": { "de": "Expression der Glykoproteine B7-H1 und B7-H3 auf Tumorzellen von Patienten mit metastasiertem, klarzelligem Nierenzellkarzinom. Einfluss der Glykoproteine auf die Prognose", "en": "Expression der Glykoproteine B7-H1 und B7-H3 auf Tumorzellen von Patienten mit metastasiertem, klarzelligem Nierenzellkarzinom. Einfluss der Glykoproteine auf die Prognose" }, "short": "Expression der Glykoproteine B7-H3", "url": null, "abstract": { "de": "Das metastasierte Nierenzellkarzinom ist ein aggressiver Tumor der weder strahlen- noch chemosensibel ist. Auftretende singuläre Metastasen werden wenn möglich immer chirurgisch entfernt. Bei multipler Metastasierung kommt eine Immuntherapie sowie eine Anti-angiogenetische Therapie oder auch eine Kombination aus beiden zur Anwendung. In den letzten 20 Jahren war die Immuntherapie die einzig erfolgreiche Therapie bei diesen Patienten. In den letzten Jahren wurden eine Reihe von co-inhibitorischen und co-stimulatorischen Molekülen auf Zellen des Immunsystems aber auch auf Tumorzellen gefunden. Diese Moleküle können einzelne Zellen im Immunsystem blockieren oder aber stimulieren.\r\nWir glauben, dass Patienten die die co-inhibitorischen Moleküle B7-H1 und B7-H3 an ihrer Oberfläche exprimieren, eine unterdrückte Immunabwehr haben und, dass diese Patienten aus diesem Grund schlecht auf einen Immuntherapie ansprechen und früher versterben. \r\nUnser Ziel ist es, das Gewebe aller Patienten die wir in den letzten 15 Jahren mit einer Immuntherapie behandelt haben zu färben und zu evaluieren ob sie B7-H1 und B7-H3 exprimieren.\r\nEs wäre von großem Vorteil Patienten von vornherein identifizieren zu können, die auf eine Immuntherapie ansprechen. Dadurch könnte den Patienten die nicht ansprechen von vornherein eine oft recht nebenwirkungsreiche Therapie erspart werden.", "en": "Das metastasierte Nierenzellkarzinom ist ein aggressiver Tumor der weder strahlen- noch chemosensibel ist. Auftretende singuläre Metastasen werden wenn möglich immer chirurgisch entfernt. Bei multipler Metastasierung kommt eine Immuntherapie sowie eine Anti-angiogenetische Therapie oder auch eine Kombination aus beiden zur Anwendung. In den letzten 20 Jahren war die Immuntherapie die einzig erfolgreiche Therapie bei diesen Patienten. In den letzten Jahren wurden eine Reihe von co-inhibitorischen und co-stimulatorischen Molekülen auf Zellen des Immunsystems aber auch auf Tumorzellen gefunden. Diese Moleküle können einzelne Zellen im Immunsystem blockieren oder aber stimulieren.\r\nWir glauben, dass Patienten die die co-inhibitorischen Moleküle B7-H1 und B7-H3 an ihrer Oberfläche exprimieren, eine unterdrückte Immunabwehr haben und, dass diese Patienten aus diesem Grund schlecht auf einen Immuntherapie ansprechen und früher versterben. \r\nUnser Ziel ist es, das Gewebe aller Patienten die wir in den letzten 15 Jahren mit einer Immuntherapie behandelt haben zu färben und zu evaluieren ob sie B7-H1 und B7-H3 exprimieren.\r\nEs wäre von großem Vorteil Patienten von vornherein identifizieren zu können, die auf eine Immuntherapie ansprechen. Dadurch könnte den Patienten die nicht ansprechen von vornherein eine oft recht nebenwirkungsreiche Therapie erspart werden." }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-05-01T02:00:00+02:00", "end_planned": "2009-07-01T02:00:00+02:00", "end_effective": "2010-12-31T01:00:00+01:00", "assignment": "2009-09-22T13:07:22+02:00", "program": null, "subprogram": null, "organization": 14056, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 1719, "title": { "de": "GATiB II - Koordination", "en": "GATiB II - Coordination" }, "short": "GATIB_II_Koordination", "url": null, "abstract": { "de": "Biobanken für die biomedizinische Forschung sind Sammlungen von biologischem Material (Gewebe, Zellen, Blut, Körperflüssigkeiten, inklusive der daraus isolierten Biomoleküle) und den zugehörigen Daten über den Probendonor. Diese biologischen Materialien enthalten wertvolle Informationen über genetische und nicht-genetische Krankheitsursachen und über Faktoren, die den Krankheitsverlauf beeinflussen. Aufgrund dieser Relevanz sehen mehrere internationale Organisationen biologische Materialien als essentielle Rohmaterialien, um den Fortschritt in Biotechnologie und Gesundheitswesen voranzutreiben.\r\nGATiB basiert auf einem einzigartigen Pathologiearchiv an der Medizinischen Universität Graz und enthält über 3 Millionen Proben von 800.000 Patienten, die nahezu alle Krankheiten einer mitteleuropäischen Bevölkerung in der natürlichen Häufigkeit abbilden.\r\n\r\nGEN-AU I förderte die Umwandlung dieses Archivs in eine Biobank (GATiB)\r\nSchwerpunkt in GEN-AU II war die Erhöhung des wissenschaftlichen Wertes und des Nutzens der 3 Millionen archivierter Proben durch halbautomatische Annotation der Proben mit medizinischen Daten und Patienten-Überlebensdaten.\r\nIn GEN-AU III wird GATiB II den Schwerpunkt auf die prospektive Sammlung von Proben und Daten, sowie internationale Integration legen. Es ist eine Probensammlung geplant, deren Design spezifisch die Forschung an metabolischen Erkrankungen unterstützt - eine anerkannte Stärke der Forschung an der Medizinischen Universität und den anderen Grazer Universitäten. Dies erfordert die Entwicklung verbesserter Gefrierkonservierungs- und Gefrierlagermethoden für Gewebe um das Potenzial moderner metabolomischer Analysemethoden optimal ausnützen zu können.", "en": "Biobanken für die biomedizinische Forschung sind Sammlungen von biologischem Material (Gewebe, Zellen, Blut, Körperflüssigkeiten, inklusive der daraus isolierten Biomoleküle) und den zugehörigen Daten über den Probendonor. Diese biologischen Materialien enthalten wertvolle Informationen über genetische und nicht-genetische Krankheitsursachen und über Faktoren, die den Krankheitsverlauf beeinflussen. Aufgrund dieser Relevanz sehen mehrere internationale Organisationen biologische Materialien als essentielle Rohmaterialien, um den Fortschritt in Biotechnologie und Gesundheitswesen voranzutreiben.\r\nGATiB basiert auf einem einzigartigen Pathologiearchiv an der Medizinischen Universität Graz und enthält über 3 Millionen Proben von 800.000 Patienten, die nahezu alle Krankheiten einer mitteleuropäischen Bevölkerung in der natürlichen Häufigkeit abbilden.\r\n\r\nGEN-AU I förderte die Umwandlung dieses Archivs in eine Biobank (GATiB)\r\nSchwerpunkt in GEN-AU II war die Erhöhung des wissenschaftlichen Wertes und des Nutzens der 3 Millionen archivierter Proben durch halbautomatische Annotation der Proben mit medizinischen Daten und Patienten-Überlebensdaten.\r\nIn GEN-AU III wird GATiB II den Schwerpunkt auf die prospektive Sammlung von Proben und Daten, sowie internationale Integration legen. Es ist eine Probensammlung geplant, deren Design spezifisch die Forschung an metabolischen Erkrankungen unterstützt - eine anerkannte Stärke der Forschung an der Medizinischen Universität und den anderen Grazer Universitäten. Dies erfordert die Entwicklung verbesserter Gefrierkonservierungs- und Gefrierlagermethoden für Gewebe um das Potenzial moderner metabolomischer Analysemethoden optimal ausnützen zu können." }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-10-01T02:00:00+02:00", "end_planned": "2012-04-30T02:00:00+02:00", "end_effective": "2012-09-30T02:00:00+02:00", "assignment": "2009-01-15T10:26:42+01:00", "program": 73, "subprogram": null, "organization": 14020, "category": 10, "type": 10, "partner_function": 3, "manager": 51663, "contact": 51663, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 152 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1719-50828-12", "1719-51663-10" ] }, { "id": 1777, "title": { "de": "The role of C/EBPa on the development of monocyte subsets", "en": "The role of C/EBPa on the development of monocyte subsets" }, "short": "C/EBPa", "url": null, "abstract": { "de": "The integrity of the hematopoietic system depends on a large number of blood cell lineages being continuously replenished from a rare population of pluripotent heatopoietic stem cells(HSC), representing a paradigm for how multilineage diversity can be achieved from a common stem cell through lineage commitment and subsequent differentiation.\r\nMonocytes are mononuclear cells and represent about 10% of leukocytes in human blood and 4% of leukocytes in mouse blood. The best known function of monocytes is their role as accessory cells, which link inflammation and the innate defense system against microorganisms to adaptive immune response.\r\nMany factors are involved in monocyte differentiation like PU.1, IRF8, KLF-4, MafB, c-maf and C/EBPalpha. C/EBPalpha (CCAAT/enhancer binding protein alpha) is a basic region-leucine zipper transcription factor and indispensable for formation of mature neutrophils and eosinophils. It is expressed at low levels in HSC, and is up-regulated to its highest levels in GMP(granulocyte/monocyte progenitors), whereas it is not expressed in precursors of lymphoid cells and is downregulated as CMP differentiate to MEP(megakaryocyte/erythrocyte progenitors). Mice-studies indicate that C/EBPalpha is essential for transition of CMP to GMP.\r\n\r\nWe hypothesize that C/EBPalpha positive and C/EBPalpha negative monocytes represent distinct subgroups of monocytes, which also differ in their function. In addition, we speculate that they are derived from different progenitors. To experimentally approach this hypothesis we want to use the C/EBPalphaCRE EYFP reporter mouse model.", "en": "The integrity of the hematopoietic system depends on a large number of blood cell lineages being continuously replenished from a rare population of pluripotent heatopoietic stem cells(HSC), representing a paradigm for how multilineage diversity can be achieved from a common stem cell through lineage commitment and subsequent differentiation.\r\nMonocytes are mononuclear cells and represent about 10% of leukocytes in human blood and 4% of leukocytes in mouse blood. The best known function of monocytes is their role as accessory cells, which link inflammation and the innate defense system against microorganisms to adaptive immune response.\r\nMany factors are involved in monocyte differentiation like PU.1, IRF8, KLF-4, MafB, c-maf and C/EBPalpha. C/EBPalpha (CCAAT/enhancer binding protein alpha) is a basic region-leucine zipper transcription factor and indispensable for formation of mature neutrophils and eosinophils. It is expressed at low levels in HSC, and is up-regulated to its highest levels in GMP(granulocyte/monocyte progenitors), whereas it is not expressed in precursors of lymphoid cells and is downregulated as CMP differentiate to MEP(megakaryocyte/erythrocyte progenitors). Mice-studies indicate that C/EBPalpha is essential for transition of CMP to GMP.\r\n\r\nWe hypothesize that C/EBPalpha positive and C/EBPalpha negative monocytes represent distinct subgroups of monocytes, which also differ in their function. In addition, we speculate that they are derived from different progenitors. To experimentally approach this hypothesis we want to use the C/EBPalphaCRE EYFP reporter mouse model." }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-08-01T02:00:00+02:00", "end_planned": "2010-04-30T02:00:00+02:00", "end_effective": "2013-07-31T02:00:00+02:00", "assignment": "2009-04-07T10:52:48+02:00", "program": null, "subprogram": null, "organization": 14082, "category": 10, "type": 10, "partner_function": 4, "manager": 51911, "contact": 51911, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 423 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1777-58889-12", "1777-51911-10" ] }, { "id": 1908, "title": { "de": "GATiB II - Subprojekt 1", "en": "GATiB II - Subproject 1" }, "short": "GATiB II - Subprojekt 1", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-10-01T02:00:00+02:00", "end_planned": "2012-04-30T02:00:00+02:00", "end_effective": "2012-09-30T02:00:00+02:00", "assignment": "2009-09-03T17:01:48+02:00", "program": 73, "subprogram": null, "organization": 14020, "category": 10, "type": 10, "partner_function": 2, "manager": 51663, "contact": 51663, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 152 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1908-51663-10" ] }, { "id": 1882, "title": { "de": "Analysis of drug-metabolizing enzyme polymorphisms for response to anthracycline-based neoadjuvant chemotherapy in breast cancer", "en": "Analysis of drug-metabolizing enzyme polymorphisms for response to anthracycline-based neoadjuvant chemotherapy in breast cancer" }, "short": "CHEMOTHERAP_BREAST CANCER", "url": null, "abstract": { "de": "Breast cancer is the most common malignancy affecting women. It is the second leading cause of cancer-related death in Europe and the United States. Despite several improvements in early diagnosis, surgical techniques and hormone-, immune- and chemotherapy, this disease remains a threat to life for a large number of women. Moreover, providing individual treatment with low toxicity but maximum benefit is still an unsolved problem.\r\nNeoadjuvant chemotherapy using anthracycline-containing regimes is a standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. The main goal of neoadjuvant chemotherapy is to eliminate potential micrometastasis, thus improving disease-free survial.\r\nPharmacogenetics is aimed at understanding and predicting an individual's drug response based upon genetic variation.\r\n\r\nIn this pharmacogenetic project we investigate a set of heritable genetic factors in drug-metabolizing enzymes that might predict drug-induced anti-tumor response and toxicity of anthracycline-based neoadjuvant therapy in breast cancer, based upon multigenetic analysis.", "en": "Breast cancer is the most common malignancy affecting women. It is the second leading cause of cancer-related death in Europe and the United States. Despite several improvements in early diagnosis, surgical techniques and hormone-, immune- and chemotherapy, this disease remains a threat to life for a large number of women. Moreover, providing individual treatment with low toxicity but maximum benefit is still an unsolved problem.\r\nNeoadjuvant chemotherapy using anthracycline-containing regimes is a standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. The main goal of neoadjuvant chemotherapy is to eliminate potential micrometastasis, thus improving disease-free survial.\r\nPharmacogenetics is aimed at understanding and predicting an individual's drug response based upon genetic variation.\r\n\r\nIn this pharmacogenetic project we investigate a set of heritable genetic factors in drug-metabolizing enzymes that might predict drug-induced anti-tumor response and toxicity of anthracycline-based neoadjuvant therapy in breast cancer, based upon multigenetic analysis." }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-05-01T02:00:00+02:00", "end_planned": "2009-09-30T02:00:00+02:00", "end_effective": "2010-09-30T02:00:00+02:00", "assignment": "2009-08-03T14:52:33+02:00", "program": null, "subprogram": null, "organization": 14085, "category": 10, "type": 10, "partner_function": 4, "manager": 58814, "contact": 58814, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 457 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1882-58814-10" ] }, { "id": 2151, "title": { "de": "Entwicklung eines praktikablen Werkzeugs für die Bewertung und Implementierung evidenzbasierter Leitlinien in Kooperation mit den Krankenhäusern in der Steiermark", "en": "Entwicklung eines praktikablen Werkzeugs für die Bewertung und Implementierung evidenzbasierter Leitlinien in Kooperation mit den Krankenhäusern in der Steiermark" }, "short": "EVIDENZBASIERTE LEITLINIEN", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-05-01T02:00:00+02:00", "end_planned": "2011-04-30T02:00:00+02:00", "end_effective": "2011-04-30T02:00:00+02:00", "assignment": "2010-03-04T12:31:15+01:00", "program": null, "subprogram": null, "organization": 14026, "category": 10, "type": 10, "partner_function": 4, "manager": 51098, "contact": 51098, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2151-51098-10" ] }, { "id": 1720, "title": { "de": "GATIB II, Genome Austria Tissue Bank (GEN-AU III)", "en": "GATIB II, Genome Austria Tissue Bank (GEN-AU III)" }, "short": "GATIB II_GENAU_III_Trauner", "url": null, "abstract": { "de": "Biobanken für die biomedizinische Forschung sind Sammlungen von biologischem Material (Gewebe, Zellen, Blut, Körperflüssigkeiten, inklusive der daraus isolierten Biomoleküle) und den zugehörigen Daten über den Probendonor. Diese biologischen Materialien enthalten wertvolle Informationen über genetische und nicht-genetische Krankheitsursachen und über Faktoren, die den Krankheitsverlauf beeinflussen. Aufgrund dieser Relevanz sehen mehrere internationale Organisationen biologische Materialien als essentielle Rohmaterialien, um den Fortschritt in Biotechnologie und Gesundheitswesen voranzutreiben.\r\nGATiB basiert auf einem einzigartigen Pathologiearchiv an der Medizinischen Universität Graz und enthält über 3 Millionen Proben von 800.000 Patienten, die nahezu alle Krankheiten einer mitteleuropäischen Bevölkerung in der natürlichen Häufigkeit abbilden.\r\n\r\nGEN-AU I förderte die Umwandlung dieses Archivs in eine Biobank (GATiB)\r\nSchwerpunkt in GEN-AU II war die Erhöhung des wissenschaftlichen Wertes und des Nutzens der 3 Millionen archivierter Proben durch halbautomatische Annotation der Proben mit medizinischen Daten und Patienten-Überlebensdaten.\r\nIn GEN-AU III wird GATiB II den Schwerpunkt auf die prospektive Sammlung von Proben und Daten, sowie internationale Integration legen. Es ist eine Probensammlung geplant, deren Design spezifisch die Forschung an metabolischen Erkrankungen unterstützt - eine anerkannte Stärke der Forschung an der Medizinischen Universität und den anderen Grazer Universitäten. Dies erfordert die Entwicklung verbesserter Gefrierkonservierungs- und Gefrierlagermethoden für Gewebe um das Potenzial moderner metabolomischer Analysemethoden optimal ausnützen zu können.", "en": "Biobanken für die biomedizinische Forschung sind Sammlungen von biologischem Material (Gewebe, Zellen, Blut, Körperflüssigkeiten, inklusive der daraus isolierten Biomoleküle) und den zugehörigen Daten über den Probendonor. Diese biologischen Materialien enthalten wertvolle Informationen über genetische und nicht-genetische Krankheitsursachen und über Faktoren, die den Krankheitsverlauf beeinflussen. Aufgrund dieser Relevanz sehen mehrere internationale Organisationen biologische Materialien als essentielle Rohmaterialien, um den Fortschritt in Biotechnologie und Gesundheitswesen voranzutreiben.\r\nGATiB basiert auf einem einzigartigen Pathologiearchiv an der Medizinischen Universität Graz und enthält über 3 Millionen Proben von 800.000 Patienten, die nahezu alle Krankheiten einer mitteleuropäischen Bevölkerung in der natürlichen Häufigkeit abbilden.\r\n\r\nGEN-AU I förderte die Umwandlung dieses Archivs in eine Biobank (GATiB)\r\nSchwerpunkt in GEN-AU II war die Erhöhung des wissenschaftlichen Wertes und des Nutzens der 3 Millionen archivierter Proben durch halbautomatische Annotation der Proben mit medizinischen Daten und Patienten-Überlebensdaten.\r\nIn GEN-AU III wird GATiB II den Schwerpunkt auf die prospektive Sammlung von Proben und Daten, sowie internationale Integration legen. Es ist eine Probensammlung geplant, deren Design spezifisch die Forschung an metabolischen Erkrankungen unterstützt - eine anerkannte Stärke der Forschung an der Medizinischen Universität und den anderen Grazer Universitäten. Dies erfordert die Entwicklung verbesserter Gefrierkonservierungs- und Gefrierlagermethoden für Gewebe um das Potenzial moderner metabolomischer Analysemethoden optimal ausnützen zu können." }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-10-01T02:00:00+02:00", "end_planned": "2012-04-30T02:00:00+02:00", "end_effective": "2012-06-30T02:00:00+02:00", "assignment": "2009-01-15T10:32:33+01:00", "program": 73, "subprogram": null, "organization": 14081, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 152 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2398, "title": { "de": "SIMNET STYRIA 2009/2010", "en": "SIMNET STYRIA 2009/2010" }, "short": "SIMNET", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-05-18T02:00:00+02:00", "begin_effective": "2009-05-18T02:00:00+02:00", "end_planned": "2011-05-31T02:00:00+02:00", "end_effective": "2011-05-31T02:00:00+02:00", "assignment": "2011-02-07T14:48:55+01:00", "program": null, "subprogram": null, "organization": 14011, "category": 10, "type": 10, "partner_function": 2, "manager": 50966, "contact": 50966, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2398-50966-10" ] } ] }